Top in women’s health: FDA warning for fezolinetant; trauma may be toxic for brain health

The FDA issued a warning that use of fezolinetant can cause rare but serious liver injury following a report of a patient with signs and symptoms of liver injury after taking the nonhormonal medication
The agent received FDA approval in May 2023 for the treatment of menopausal hot flashes.
“This change in the FDA prescribing recommendations for fezolinetant should not discourage women from using this effective therapy for management of hot flashes,” Stephanie S. Faubion, MD, MBA, NCMP, IF, director of the Mayo Clinic Center for Women’s Health and medical director of The

The FDA issued a warning that use of fezolinetant can cause rare but serious liver injury following a report of a patient with signs and symptoms of liver injury after taking the nonhormonal medication
The agent received FDA approval in May 2023 for the treatment of menopausal hot flashes.
“This change in the FDA prescribing recommendations for fezolinetant should not discourage women from using this effective therapy for management of hot flashes,” Stephanie S. Faubion, MD, MBA, NCMP, IF, director of the Mayo Clinic Center for Women’s Health and medical director of The